Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$12.86 USD
-0.41 (-3.09%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $12.92 +0.06 (0.47%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Stoke Therapeutics, Inc. [STOK]
Reports for Purchase
Showing records 1 - 20 ( 96 total )
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Removal of the Partial Clinical Hold Shows FDA?s Increasing Confidence on STK-001
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
All Cylinders Firing As We Await Zorevunersen Updates In 2H24
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Check In With Management and Thoughts On Upcoming Catalysts
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STK-001 Has the Potential to Be Disease-Modifying - Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory Discussions On Deck As We Await Phase 3 Design For STK-001
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Impact on Cognition and Behavior Differentiates STK-001 in the Landscape; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Feeling Pretty STOKed On STK-001 Update; Increasing Target to $17
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AES Data Highlights the Importance of Loading Dose, Indicates Target Engagement in Required Brain Regions in DS Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Invite: Epilepsy KOL Check - AES Wrap and Thoughts Into 2024
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STK-001 Promises Long Lasting Impact for Dravet Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Steady Sailing Into AES Meeting, 1Q24 Update [3Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Stoke Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
KOL Remains Enthusiastic About STK-001?s MOA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A